Daily Cardiology Research Analysis
Three impactful cardiology studies span mechanistic discovery, therapeutic innovation, and evidence synthesis. A European Heart Journal study identifies an endothelial HEG1–CUL3–PHACTR1–SP1 pathway that controls eNOS and blood pressure via shear stress signaling. A Nature Communications paper links macrophage ferroptosis to pulmonary veno-occlusive disease in GCN2 deficiency and shows pharmacologic reversal with a ferroptosis inhibitor, while a meta-analysis of randomized trials finds direct ora
Summary
Three impactful cardiology studies span mechanistic discovery, therapeutic innovation, and evidence synthesis. A European Heart Journal study identifies an endothelial HEG1–CUL3–PHACTR1–SP1 pathway that controls eNOS and blood pressure via shear stress signaling. A Nature Communications paper links macrophage ferroptosis to pulmonary veno-occlusive disease in GCN2 deficiency and shows pharmacologic reversal with a ferroptosis inhibitor, while a meta-analysis of randomized trials finds direct oral anticoagulants comparable to warfarin for left ventricular thrombus.
Research Themes
- Endothelial mechanotransduction and hypertension pathophysiology
- Ferroptosis and macrophage biology in pulmonary vascular disease
- Anticoagulation strategy for left ventricular thrombus
Selected Articles
1. Shear stress-induced endothelial HEG1 signalling regulates vascular tone and blood pressure.
Using multi-cohort human data, CFD, single-cell sequencing, and endothelial-specific knockout mice, the authors show that HEG1 is a shear-stress sensor that restrains blood pressure by enabling CUL3-mediated degradation of PHACTR1, permitting SP1-driven eNOS transcription and NO production. Loss of HEG1 reduces vasodilation and elevates blood pressure, while pharmacologic inhibition of PHACTR1 nuclear localization rescues the phenotype.
Impact: This study uncovers a mechanistically coherent endothelial pathway that links hemodynamic forces to NO bioavailability and systemic blood pressure, identifying actionable nodes (HEG1–PHACTR1) for antihypertensive therapy.
Clinical Implications: HEG1 and PHACTR1 may serve as biomarkers of impaired shear signaling and potential therapeutic targets to restore NO-dependent vasodilation in hypertension, guiding precision vascular therapies.
Key Findings
- Plasma HEG1 is reduced in hypertension due to diminished endothelial wall shear stress, correlating with lower endothelial HEG1 expression.
- Endothelial Heg1 deletion elevates blood pressure and impairs endothelium-dependent vasodilation, accentuated on an ApoeKO background.
- HEG1 promotes CUL3-mediated degradation of PHACTR1; its loss increases PHACTR1 nuclear translocation, suppressing SP1-driven eNOS transcription and NO production.
- Blocking PHACTR1 nuclear localization (CCG-1423) rescues vasodilation and blood pressure phenotypes.
Methodological Strengths
- Multimodal translational design combining human cohorts, CFD modeling, single-cell RNA-seq, and endothelial-specific knockout mice
- Mechanistic validation with proteomics, transcriptomics, and ubiquitination assays plus pharmacologic rescue
Limitations
- No randomized clinical intervention; translational gap from preclinical mechanisms to patient-level BP outcomes
- HEG1 measurement and therapeutic targeting strategies require clinical feasibility and safety studies
Future Directions: Develop HEG1/PHACTR1-targeted agents; validate HEG1 as a biomarker of shear signaling; test pathway modulation on ambulatory BP and vascular function in early-phase trials.
BACKGROUND AND AIMS: Endothelial cells (ECs) sense flow shear stress for vasodilation, a crucial mechanism for maintaining systemic blood pressure (BP). Impaired shear stress signalling contributes to endothelial dysfunction and hypertension. Heart development protein with EGF-like domain 1 (HEG1), a flow-sensitive, endothelial-derived protein, is inversely associated with cardiovascular risks. This study aimed to elucidate the role of endothelial HEG1 in BP regulation and the underlying mechanisms. METHODS: Phenome-wide association study, computational fluid dynamics analysis, single-cell RNA sequencing, artery and plasma samples from independent cohorts, and in vitro shear stress analysis were used to assess the association between hypertension, shear stress, and HEG1 levels. Endothelial-specific Heg1 deletion mice, BP monitoring, and vascular function analysis were employed to characterize the roles of EC-HEG1 in endothelial function and hypertension. Proteomics, transcriptomics, and ubiquitination assays were used to identify the regulatory pathways involved. RESULTS: Plasma HEG1 levels were down-regulated in hypertensive subjects due to reduced wall shear stress on the endothelium, which diminished HEG1 expression and its release into circulation. Endothelial-specific Heg1 deletion in mice resulted in elevated BP, impaired endothelium-dependent vasodilation, and hypertensive levels especially in an ApoeKO dyslipidaemia background. Mechanistically, HEG1 facilitated CUL3-mediated degradation of PHACTR1. HEG1 deletion led to increased PHACTR1 levels, nuclear translocation, and suppression of SP1-mediated eNOS transcription and NO production. Inhibition of PHACTR1 nuclear localization by CCG-1423 prevented impaired vasodilation and hypertension. CONCLUSIONS: Our study identifies a novel shear-sensitive endothelial HEG1 signalling pathway in BP regulation, providing potential therapeutic targets for hypertension.
2. Macrophage ferroptosis potentiates GCN2 deficiency induced pulmonary venous arterialization.
In PVOD, scRNA-seq and histology identify macrophages as the key cell type altered by GCN2 (EIF2AK4) deficiency, with upregulation of ferroptosis-related pathways. Pharmacologic ferroptosis inhibition (ferrostatin-1) reverses adverse hemodynamic changes in a GCN2-deficient model, implicating macrophage ferroptosis as a modifiable driver of pulmonary venous remodeling.
Impact: Reveals a targetable cell-death mechanism in a lethal pulmonary vascular disease with limited therapies, supporting ferroptosis modulation as a new treatment avenue.
Clinical Implications: Ferroptosis inhibitors could be explored as disease-modifying therapy in PVOD, and macrophage ferroptosis signatures might guide patient stratification.
Key Findings
- Macrophages are the primary cell population affected by GCN2 (EIF2AK4) deficiency in PVOD lungs with upregulated ferroptosis pathways.
- Ferroptosis inhibition with ferrostatin-1 reverses adverse hemodynamic changes in a GCN2-deficient model.
- Data implicate macrophage ferroptosis as a mechanistic driver of pulmonary venous arterialization/remodeling.
Methodological Strengths
- Use of human PVOD lung tissues with scRNA-seq and immunohistochemistry for cell-type resolution
- Pharmacologic rescue in a genetically defined (GCN2-deficient) model demonstrating causality
Limitations
- Preclinical evidence with limited details on long-term outcomes and off-target effects of ferroptosis inhibition
- Translational applicability and optimal dosing in humans remain to be defined
Future Directions: Validate macrophage ferroptosis signatures in larger PVOD cohorts; test ferroptosis modulators in advanced preclinical models; design early-phase trials with biomarker endpoints.
Pulmonary veno-occlusive disease (PVOD) is a fatal disease characterized by the remodelling of pulmonary veins and haemosiderin accumulation in macrophages. Although (General Control Nonderepressible 2) GCN2 deficiency has been reported in PVOD patients, the underlying mechanism by which GCN2 deficiency affects the pulmonary venous cells and the surrounding cells, remains unclear. Here, we perform immunohistochemistry and scRNA-sequencing analyses to show that macrophages are the major population affected by GCN2 deficiency and ferroptosis pathway-related genes are upregulated in lung macrophages of PVOD patients. Treatment with the specific ferroptosis inhibitor ferrostatin-1 (Fer-1) reverses the changes in haemodynamic indices observed in Eif2ak4
3. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist in patients with left ventricular thrombus: A meta-analysis of randomized controlled trials.
Across eight randomized trials (n=576), DOACs matched VKAs in LV thrombus resolution and showed no significant differences in stroke/systemic embolism, major bleeding, or mortality. These findings support DOACs as a viable alternative to warfarin for LV thrombus management.
Impact: Provides randomized evidence synthesis to inform anticoagulant choice in LV thrombus, an area historically guided by observational data.
Clinical Implications: DOACs can be considered when warfarin is unsuitable or INR control is problematic, with similar thrombus resolution and safety; shared decision-making should account for drug–drug interactions and renal function.
Key Findings
- Thrombus resolution rates were similar between DOACs (88.9%) and VKAs (81.7%) with pooled RR 1.01 (95% CI 0.94–1.07).
- No significant differences in stroke, systemic embolism, composite thromboembolism, major bleeding, or all-cause mortality.
- Network meta-analysis did not identify superiority of any specific anticoagulant across endpoints.
Methodological Strengths
- Restriction to randomized controlled trials with random-effects synthesis
- Assessment of both efficacy (thrombus resolution) and safety outcomes including bleeding and mortality
Limitations
- Total sample size remains modest with low event rates, limiting power for rare outcomes
- Heterogeneity in imaging follow-up protocols and DOAC agents/dosing across trials
Future Directions: Head-to-head adequately powered RCTs with standardized imaging and longer follow-up to confirm non-inferiority and explore agent-specific effects.
BACKGROUND: While vitamin K antagonist (VKA) has traditionally been the preferred treatment for left ventricle (LV) thrombus, the comparative efficacy and safety of direct oral anticoagulants (DOACs) with VKA in this setting remain unelucidated. METHODS: A comprehensive literature search of PubMed and Google Scholar was conducted through May 7, 2025, to identify randomized controlled trials (RCTs) comparing DOACs with VKA in patients with LV thrombus. The primary endpoint was complete resolution of LV thrombus. Secondary endpoints included stroke, systemic embolism, the composite of both stroke and systemic embolism, major bleeding, and all-cause mortality. Both pairwise and network meta-analyses were performed using a random-effects model to synthesize the effect estimates. RESULTS: Eight RCTs comprising a total of 576 patients were included. Collectively, 88.9 % of the patients treated with DOACs and 81.7 % of those receiving VKA experienced LV thrombus resolution, with a synthesized risk ratio (RR) of 1.01 [95 % confidence interval (CI), 0.94 to 1.07]. No significant differences were observed between the two groups for stroke (RR, 0.75; 95 % CI, 0.25 to 2.19), systemic embolism (RR, 0.21; 95 % CI, 0.01 to 4.58), the composite of stroke and systemic embolism (RR, 0.64; 95 % CI, 0.17 to 2.32), major bleeding (RR, 0.43; 95 % CI, 0.16 to 1.19), or all-cause mortality (RR, 0.92; 95 % CI, 0.36 to 2.31). A network meta-analysis showed no statistically significant differences across the anticoagulants in any clinical endpoint. CONCLUSION: DOACs showed comparable efficacy and safety to VKA in managing LV thrombus, supporting their potential role as a viable alternative anticoagulation strategy.